Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Days Payable is 17.76 as of Dec. 2025, which is 86% below its 10-year median of 126.45. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.72 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, CanSino Biologics ranks better than 56.96% on this metric.
The historical rank and industry rank for CanSino Biologics's Days Payable or its related term are showing as below:
CASBF'
s Days Payable Range Over the Past 10 Years
Min: 54.16 Med: 126.45 Max: 877.39
Current: 103.15
During the past 10 years, CanSino Biologics's highest Days Payable was 877.39. The lowest was 54.16. And the median was 126.45.
CASBF's Days Payable is ranked better than 56.96% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs CASBF: 103.15
CanSino Biologics's Days Payable
declined
from Jun. 2024 (132.23) to Dec. 2025 (17.76).
It may suggest that CanSino Biologicsaccelerated paying its suppliers.
CanSino Biologics Days Payable Related Terms
CanSino Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CanSino Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Days Payable of 17.76 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CanSino Biologics and its competitors. This is 86% below median its historical median of 126.45. Over the past decade, CanSino Biologics' Days Payable has ranged from 54.16 to 877.39. According to the industry distribution chart, CanSino Biologics ranks #399 out of 927 companies in the Drug Manufacturers industry, placing it in the top 43%.
Is CanSino Biologics' Days Payable too high?
CanSino Biologics' current Days Payable of 17.76 is 86% below median its 10-year median of 126.45. Over the past 10 years, this metric has ranged from a low of 54.16 to a high of 877.39. The Drug Manufacturers industry median Days Payable is 90.38. CanSino Biologics' value of 17.76 is 80.3% below this industry median. Based on the distribution chart, CanSino Biologics ranks #399 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #399 out of 927 companies for Days Payable. This puts CanSino Biologics in the upper half of its industry. The industry median Days Payable is 90.38. CanSino Biologics' value of 17.76 is 80.3% below this benchmark. Historically, CanSino Biologics' own Days Payable has ranged from 54.16 to 877.39 over the past decade. While the company's 10-year median is 126.45 vs. the industry median of 90.38, CanSino Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Days Payable of 17.76 is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Days Payable is 17.76, which is 86% below median its own 10-year median of 126.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Days Payable is 17.76, which is 86% below median its 10-year median of 126.45 and 80.3% below the Drug Manufacturers industry median of 90.38. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Days Payable is 17.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.72.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Days Payable: 17.76 (86% below median its 10-year median of 126.45)
GF Value™: $8.72 vs. price of $2.60 (70.2% below fair value)
Industry Position: 80.3% below the Drug Manufacturers median (#399 of 927)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
